S1 File: Supplement 1 Effect of dexamethasone exposure on the neonatal unit on 2 adolescent lung function 3 Christopher Harris, Siobhan Crichton, Sanja Zivanovic, Alan Lunt, Sandy Calvert, Neil 4 Marlow, Janet L Peacock, Anne Greenough 5 6 List of tables in S1 file: supplement 7 Table A: Lung function at follow up of children with and without complete data. 8 Table B: Baseline characteristics of the infants included and not included due to missing lung 9 function data 10 11 Table C: Mean FEF₇₅ z-score by neonatal factors (n=179) Table D: Lung function and postnatal dexamethasone exposure: sensitivity analyses adjusted 12 for confounding using propensity score matching 13 Table E: Sensitivity analyses adjusting for antenatal steroids and postnatal surfactant 14 Table F: Random effects estimates from adjusted models presented in table 2 main paper 15 16 Further Baseline data (S1 file: Online supplement. Tables A-C) 17 Table A shows lung function at follow up in children with or without complete data and 18 shows little evidence of bias in our dataset. 19 Table B shows reasonable balance according to whether follow-up lung function data were or 20 were not available. 21 Table C gives mean FEF₇₅ z-score by neonatal factors and shows that most neonatal factors 22 had a limited effect on later lung function. This supports our suggestion that the observed 23 24 effects of dexamethasone are unlikely to be fully explained by uncontrolled confounding. 25

S1 File: Online supplement. Table A: Lung function at follow up of children with and without complete data.

	Complete covariate data	Missing covariate data	
N	Mean(SD)	Mean(SD)	p-value
	(n=179)	(n=69)	
248	-1.09 (0.89)	-1.03 (0.87)	0.748
248	-1.22 (0.92)	-1.20 (0.85)	0.837
248	-1.02 (0.95)	-0.95 (0.89)	0.403
231	-1.46 (1.11)	-1.46 (0.97)	0.995
248	-0.80 (1.10)	-0.71 (0.95)	0.563
248	-0.38 (1.02)	-0.32 (0.84)	0.769
248	-1.49 (1.88)	-1.33 (1.50)	0.527
247	83.6 (14.9)	82.9 (16.3)	0.991
211	0.54 (1.35)	0.06 (0.96)	0.018
218	0.03 (1.31)	-0.40 (1.11)	0.034
229	-0.64 (1.07)	-0.77 (1.06)	0.469
210	-0.94 (1.09)	-0.97 (1.03)	0.941
237	97.2 (23.0)	91.3 (19.6)	0.098
237	93.2 (23.0)	89.76 (22.5)	0.380
	248 248 248 248 248 248 248 248 248 247 211 218 229 210	Covariate data N Mean(SD) (n=179) 248 -1.09 (0.89) 248 -1.22 (0.92) 248 -1.02 (0.95) 231 -1.46 (1.11) 248 -0.80 (1.10) 248 -0.38 (1.02) 248 -1.49 (1.88) 247 83.6 (14.9) 211 0.54 (1.35) 218 0.03 (1.31) 229 -0.64 (1.07) 210 -0.94 (1.09)	N Mean(SD) Mean(SD) (n=179) (n=69) 248 -1.09 (0.89) -1.03 (0.87) 248 -1.22 (0.92) -1.20 (0.85) 248 -1.02 (0.95) -0.95 (0.89) 231 -1.46 (1.11) -1.46 (0.97) 248 -0.80 (1.10) -0.71 (0.95) 248 -0.38 (1.02) -0.32 (0.84) 248 -1.49 (1.88) -1.33 (1.50) 247 83.6 (14.9) 82.9 (16.3) 211 0.54 (1.35) 0.06 (0.96) 218 0.03 (1.31) -0.40 (1.11) 229 -0.64 (1.07) -0.77 (1.06) 210 -0.94 (1.09) -0.97 (1.03)

	Sample analysed with complete data N=179	Sample not analysed with incomplete data N=223	Comparison of complete and incomplete samples
Characteristics	% (n) or mean (SD)	% (n) or mean (SD)	p-value
Birth weight	882 (208)	912 (211)	0.15
Gestational age	26.5 (1.3)	26.2 (1.4)	0.06
Male sex	51% (91)	54% (125)	0.57
Multiple birth	25% (44)	22% (52)	0.59
Postnatal dexamethasone use	28% (50)	30% (70)	0.64
Oxygen dependency at 28 days	82% (147)	81% (188)	0.71
Oxygen dependency at 36 weeks PMA	59% (105)	58% (135)	0.88
Oxygen dependency at hospital discharge	24% (43)	21% (50)	0.50
Major ultrasound abnormality in neonatal period	13% (23)	15% (36)	0.46
Maternal smoking in pregnancy	23% (41)	27% (58)	0.31

S1 File: Online supplement. Table C: Mean FEF₇₅ z-score by neonatal factors (n=179)

	Mean FEF ₇₅ z-score (SD)	p-value
Birth weight		
<860g (89)	-1.12 (0.95)	0.71
≥860g (90)	-1.07 (0.83)	
Birthweight standard devaion score		
<-0.5 (90)	-1.16 (0.86)	0.28
≥-0.5 (89)	-1.02 (0.91)	
Gestational age		
23-25wk (42)	-1.11 (0.95)	0.91
26-28wk (137)	-1.09 (0.87)	
Sex		
Girl (88)	-1.00 (1.03)	0.18
Boy (91)	-1.18 (0.71)	
Multiple birth		
Singleton (135)	-1.22 (0.82)	< 0.001
Multiple (44)	-0.70 (0.98)	
Oxygen dependency at 36 weeks PMA		
No (74)	-0.95 (0.84)	0.08
Yes (105)	-1.19 (0.91)	
Neonatal cranial ultrasound		
Normal (156)	-1.09 (0.91)	0.92
Abnormal (23)	-1.11 (0.72)	
Airleak		
No (158)	-1.10 (0.89)	0.68
Yes (21)	-1.02 (0.87)	
Patent ductus arteriosus		
No (125)	-1.11 (0.92)	0.72
Yes (54)	-1.05 (0.80)	
Pulmonary haemorrhage		

No (169)	-1.07 (0.89)	0.15
Yes (10)	-1.48 (0.85)	
Mode of ventilation		
CV (90)	-1.19 (0.79)	0.13
HFOV (89)	-0.99 (0.96)	
Apgar score at 5 mins		
<9 (82)	-1.06 (0.95)	0.66
≥9 (97)	-1.12 (0.83)	
Maternal smoking in pregnancy		
No (138)	-1.01 (0.86)	0.65
Yes (41)	-1.04 (0.99)	
Antenatal steroids		
No (17)	-1.09 (0.67)	0.98
Yes (161)	-1.09 (0.91)	

Propensity Score Matching (S1 File: Online supplement. Table D)

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

Since the use of postnatal dexamethasone is so highly confounded by neonatal factors, we also used propensity score matching for dexamethasone exposure (yes/no) [S4] as an alternative way of adjustment in addition to linear mixed model regression. Propensity score (PS) matching works differently to multiple regression in that it matches the subjects as closely as possible using baseline factors prior to analysis so that the study closely resembles a randomised trial The matching algorithm used was up to three nearest neighbours for each case. This approach was used because it leads to less bias than if the single nearest neighbour approach is used without replacement [S4]. Logistic regression models were used to assign a probability of steroid use to each child based on their baseline characteristics. The model included data collected prior to the initiation of steroid use, namely: sex, birth weight, birth weight z-score, gestational age in weeks (in keeping with the original trial's randomisation strata), smoking in pregnancy, multiple birth, ventilation group and Apgar score at five minutes. Children who received dexamethasone, were then matched to three children who did not receive dexamethasone with the closest propensity scores. The main challenge of the PS method is to obtain close matches for all subjects. Inspection of the table of variables by groups before and after matching showed substantial improvement achieved by PS with no significant imbalance for any variable. It was not possible to use propensity score matching for three measures of dexamethasone exposure, that is timing of administration, number of courses and days of exposure due to

the small numbers in the different dexamethasone-use categories. For this reason, only adjustment by multivariable logistic regression was

- 49 undertaken for those measures. A further limitation of PS matching in this context is that it is difficult to adjust for clustering within propensity
- score models.

S1 File: Online supplement. Table D: Lung function and postnatal dexamethasone exposure: sensitivity analyses adjusted for confounding using propensity score matching

		No dexamethasone exposure	Dexamethasone exposure	Adjusted using mu regression (main a		Adjusted using p score matching (s	
Lung Function	N	Mean (SD)	Mean (SD)	Difference (95% CI)	p-value	Difference (95% CI)	p-value
FEF ₇₅ z score	179	-0.95 (0.91)	-1.45 (0.71)	-0.53* (-0.85 to -0.21)	0.002	-0.51 (-0.89 to -0.13)	0.009
FEF ₅₀ z score	179	-1.04 (0.89)	-1.71 (0.81)	-0.74 (-1.05 to -0.43)	<0.001	-0.54 (-0.93 to -0.14)	0.006
FEF ₂₅ z score	179	-0.82 (0.91)	-1.53 (0.86)	-0.75 (-1.07 to -0.44)	<0.001	-0.51 (-0.78 to -0.24)	< 0.001
FEF ₂₅₋₇₅ z score	169	-1.24 (1.07)	-1.98 (1.05)	-0.70 (-1.08 to -0.33)	<0.001	-0.55 (-0.99 to -0.11)	0.014
FEV ₁ z score	179	-0.55 (1.03)	-1.44 (1.03)	-0.87 (-1.24 to -0.51)	<0.001	-0.62 (-1.00 to -0.24)	0.002
FVC z score	179	-0.24 (0.96)	-0.73 (1.11)	-0.38 (-0.75 to -0.01)	0.043	-0.23 (-0.59 to 0.14)	0.221
FEV ₁ :FVC z	179	-1.17 (1.69)	-2.32 (2.11)	-1.43 (-2.09 to -0.78)	<0.001	-1.16 (-1.98 to -0.34)	0.006
PEF % pred*	178	86.07 (14.64)	77.36 (13.98)	-10.74 (-16.06 to -5.41)	<0.001	-7.42 (-11.5 to -3.4)	< 0.001
RV z score	152	0.26 (1.09)	1.29 (1.67)	0.86 (0.36 to 1.36)	0.001	0.67 (0.27 to 1.07)	0.001
FRC _{pleth} z	157	-0.11 (1.25)	0.39 (1.39)	0.39 (-0.11 to 0.90)	0.128	0.37 (0.01 to 0.73)	0.042
FRC _{he} z score	168	-0.73 (1.09)	-0.42 (1.00)	0.27 (-0.13 to 0.66)	0.186	0.30 (-0.06 to 0.67)	0.106
DL _{CO} z score	149	-0.93 (1.11)	-1.04 (1.02)	0.09 (-0.33 to 0.52)	0.658	-0.01 (-0.61 to 0.59)	0.968
At 5 Hz	170	96.06 (21.38)	100.11 (27.03)	9.57 (1.13 to 18.02)	0.026	1.22 (-5.42 to 7.86)	0.719
At 20 Hz	170	93.94	91.28	2.49	0.578	-1.57	0.669

			(< 0.5	(0.50 . 5 . 4)	
	(19.82)	(4.46)			
	l (19.84)	1 (4 40)		(-8.79 to 5.64)	
		(T.TU)	(0.27 to 11.23)	(0.7) (0 3.01)	

Further details on statistical analysis (S1 File: Online supplement. Tables E 55 and F) 56 Since differences in mean z-scores can be difficult to interpret, we have additionally 57 presented the equivalent difference in the proportion of children with abnormal lung function. 58 To do this we have used the 5th centile for normal to define the cut-off between 'normal' and 59 'abnormal'. Since in healthy children the z-score has a Normal (Gaussian) distribution, the 60 cut-point for abnormality is defined as z< -1.645, the 5th centile of the Normal Distribution. 61 The proportion abnormal is not calculated using the data values themselves but using a 62 statistical model to gain precision. These calculations are similar to those performed to 63 calculate reference ranges. The calculations used a statistical method called the 64 'distributional approach' [table 3] The distributional approach provides more precise values 65 66 than we would obtain had we used the data alone. In the present study, the adjusted estimates from the multivariable mixed model analyses were used to estimate the difference in the 67 proportion of children who have abnormal lung function in those children who were and 68 were not exposed to steroids. The calculations use the same adjusting factors to allow for 69 confounding neonatal factors as the main analyses [table 3]. 70 71 The differences for all analyses in main paper Table 2 are shown in Table 3. They show that 72 what may seem to be quite small differences in mean z-score, eg, 0.53 standard deviations for FEF₇₅, translate into quite substantial differences in the percentage that have abnormal lung 73 function results, 22 percentage points, and so the additional data help to make the results 74

more clinically meaningful.

75

- 77 Table S5 is a further sensitivity analysis that adjusts for antenatal steroids and postnatal
- surfactant. This table shows no appreciable effect of this change in the modelling. Table S6
- 79 gives the random effects estimates for the mixed effects models shown in the main paper,
- 80 table 2.

S1 File: Online supplement. Table E: Sensitivity analyses adjusting for antenatal steroids and postnatal surfactant

		No dexamethasone exposure	Dexamethasone exposure	Adjusted using original variables (Table 2 in text)	Adjusted using original variables + antenatal steroids, postnatal surfactant
Lung Function	N	Mean (SD)	Mean (SD)	Difference (exposed-unexpo) (95% CI)	Difference (exposed-unexpo) (95% CI)
FEF ₇₅ z score	179	-0.95 (0.91)	-1.45 (0.71)	-0.53 (-0.85 to -0.21)	-0.52 (-0.84 to -0.20)
FEF ₅₀ z score	179	-1.04 (0.89)	-1.71 (0.81)	-0.74 (-1.05 to -0.43)	-0.73 (-1.04 to -0.43)
FEF ₂₅ z score	179	-0.82 (0.91)	-1.53 (0.86)	-0.75 (-1.07 to -0.44)	-0.77 (-1.09 to -0.46)
FEF ₂₅₋₇₅ z score	169	-1.24 (1.07)	-1.98 (1.05)	-0.70 (-1.08 to -0.33)	-0.68 (-1.06 to -0.31)
FEV ₁ z score	179	-0.55 (1.03)	-1.44 (1.03)	-0.87 (-1.24 to -0.51)	-0.88 (-1.24 to -0.51)
FVC z score	179	-0.24 (0.96)	-0.73 (1.11)	-0.38 (-0.75 to -0.01)	-0.40 (-0.77 to -0.02)
FEV ₁ :FVC z	179	-1.17 (1.69)	-2.32 (2.11)	-1.43 (-2.09 to -0.78)	-1.42 (-2.08 to -0.75)
PEF % pred*	178	86.07 (14.64)	77.36 (13.98)	-10.74 (-16.06 to -5.41)	-10.75 (-16.15 to -5.35)
RV z score	152	0.26 (1.09)	1.29 (1.67)	0.86 (0.36 to 1.36)	0.86 (0.38 to 1.39)
FRC _{pleth} z	157	-0.11 (1.25)	0.39 (1.39)	0.39 (-0.11 to 0.90)	0.40 (-0.12 to 0.91)
FRC _{he} z score	168	-0.73 (1.09)	-0.42 (1.00)	0.27 (-0.13 to 0.66)	0.21 (-0.18 to 0.61)
DL _{CO} z score	149	-0.93 (1.11)	-1.04 (1.02)	0.09 (-0.33 to 0.52)	0.06 (-0.36 to 0.49)
At 5 Hz	170	96.06	100.11	9.57	8.60

		(21.38)	(27.03)	(1.13 to 18.02)	(0.10 to 17.10)
At 20 Hz	170	93.94	91.28	2.49	1.84
		(19.82)	(4.46)	(-6.27 to 11.25)	(-7.02 to 10.71)

- S1 File: Online supplement. Table F: Random effects estimates from adjusted models presented in table 2 main paper

Lung Function	SD Intercept	SD Residual
FEF ₇₅ z score	0.54	0.62
FEF ₅₀ z score	0.60	0.54
FEF ₂₅ z score	0.52	0.63
FEF ₂₅₋₇₅ z score	0.80	0.55
FEV ₁ z score	0.58	0.74
FVC z score	0.58	0.76
FEV ₁ :FVC z score	1.25	1.19
PEF % pred*	10.96	8.55
RV z score	0.70	0.93
FRC _{pleth} z	0.80	0.97
FRC _{he} z score	0.62	0.78
DL _{CO} z score	0.73	0.70
At 5 Hz	16.41	14.14
At 20 Hz	15.42	16.13

References

- 1. Zivanovic S, Peacock J, Alcazar-Paris M, Lo J, Lunt A, Marlow N, et al; United
- 7 Kingdom Oscillation Study Group. Late outcomes of a randomized trial of high-
- 8 frequency oscillation in neonates. N Engl J Med. 2014;370: 1121-1130.
- 2. Caliendo and Kopeinig 2003 (http://ftp.iza.org/dp1588.pdf) (web document).
- 3. Peacock JL, Sauzet O, Ewings SM, Kerry SM. Dichotomizing continuous data while
- retaining statistical power using a distributional approach. Stat Med. 2012;31:
- 12 3089–3103.
- 4. Sauzet O, Breckenkamp J, Borde T, Brenne S, David M, Razum O, et al. A
- distributional approach to obtain adjusted comparisons of proportions of a
- population at risk. Emerg Themes Epidemiol. 2016;13: 8.